The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are vital for our life sciences community. They provide early non-dilutive funding to advance high-risk, early-stage innovative research. Without action by Congress, the programs will expire on September 30, 2022. We need your help to emphasize the importance of these programs and support the advocacy work by CBSA and our national partners, including BIO, AdvaMed and PhRMA. Please act today by sending a message to our members of Congress.
Together with our partners, CBSA continues to stress the importance of SBIR and STTR to our Colorado Congressional delegation. We highlight the positive impact the programs make, funding life-saving breakthroughs for patients, supporting small businesses, and creating jobs. CBSA will continue to be loud on this topic through the reauthorization period and until Congress acts. Your…
Click here to view original post
